Profound Medical Reports Encouraging TULSA Results and Potential for Wider Access

Key Points

• A randomized trial found better preservation of erectile function and bladder control with TULSA than with robotic prostate surgery at six months.
• Additional studies reported favorable patient outcomes, but some patients experienced cancer recurrence or needed further treatment.
• Technical testing suggests TULSA could eventually work with a lower-cost MRI platform.
• Longer-term cancer-control results and further platform validation are still needed.

Profound Medical (NASDAQ: PROF) presented five research abstracts at the Interventional MRI Symposium in Boston, highlighting TULSA’s patient outcomes and potential for broader use.

Trial Shows Better Preservation of Function

In the CAPTAIN randomized trial, patients receiving whole-gland TULSA were more than twice as likely to preserve both erectile function and bladder control without pads at six months compared with robotic prostate removal.

Hospitalizations for complications were also lower—0.7% with TULSA versus 6.3% with robotic surgery. Longer-term results are still needed to assess how the treatments compare in controlling cancer.

Other Studies Add Evidence, With Some Recurrence

A Mayo Clinic Florida study of 58 patients reported 100% pad-free bladder control and preservation of erections sufficient for penetration in 87.5% of men beyond 12 months. However, 12% needed additional prostate cancer treatment during follow-up.

At Mayo Clinic Rochester, a study of 41 patients found sustained PSA reductions of approximately 62%–66% through one year, but 22% had biopsy-confirmed cancer recurrence.

A separate 197-patient registry showed that less extensive treatment was associated with shorter catheter use: seven days versus 13.5 days after whole-gland treatment.

MRI Testing Points to Potential Expansion

Researchers demonstrated technical feasibility on Siemens’ lower-field 0.55T Free.Max MRI system. This could eventually expand equipment options and reduce installation barriers.

The combined platform is not yet established as clinically validated, FDA-cleared or commercially available.

Investor Takeaway

The findings strengthen evidence for TULSA’s functional benefits and suggest a possible path to wider adoption. For PROF investors, the key milestones remain long-term cancer-control results, treatment uptake and further progress on MRI compatibility.